Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce that it has appointed Leo Lee as the company's new Chief Executive Officer and member of Board of Directors, effective immediately. Leo will succeed the outgoing CEO, John Martin, after 10 years of valuable service to the company.
Anatara Lifesciences (ASX:ANR) is pleased to announce the appointment of Dr. David Brookes as Non-Executive Director and Chair of the Audit and Risk Committee, effective from 23 January 2019.
PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.
Queensland Bauxite Limited (ASX:QBL) is most pleased to announce that the Company has received the formal approval letter for its application for reinstatement to the official list of ASX Limited.
Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $1,249,299 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive scheme.
Oventus Medical Ltd (ASX:OVN) is pleased to announce the launch of the O2Vent(R) Optima device in Australia, an important addition to the Company's sleep treatment platform.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the State Intellectual Property Office of China has granted the Company a patent for the use of biomarkers to monitor disease progression in a patient having mesenchymal cell therapy for inflammatory conditions.
